Regulus prices public offering; Imprimis acquires anti-bleeding antibiotic candidate;

 @FierceBiotech: ICYMI yesterday: First successful transplant of retinas made from embryonic stem cells. Article | Follow @FierceBiotech

 @JohnCFierce: Report: Big Pharma mounts secret attack against data transparency rule (some companies will never learn). ICYMI yesterday | Follow @JohnCFierce

 @RyanMFierce: Biogen sees 'unlikely' link between Tecfidera and patient death. Story | Follow @RyanMFierce

> Regulus Therapeutics priced its public offering of 4.5 million shares of common stock at $9.50 per share. Release

> Quest PharmaTech has partnered with AD Biotech to share research and technology development resources. AD Biotech has provided $2 million of clinical development funding to Quest and has agreed to provide up to $10 million of additional funding in return for Quest common shares and future revenue sharing. Release

> Imprimis Pharmaceuticals ($IMMY) has acquired intellectual property for IPI-120, an antibiotic drug candidate to treat bleeding and clotting. Release

Medical Device News

 @FierceMedDev: Oxford University blood test designed to screen for stress. Item | Follow @FierceMedDev

 @MarkHFierce: Google is the lead in SynapDx's $15.4M funding round - the trial for its autism Dx blood test is now under way. ICYMI yesterday | Follow @MarkHFierce

 @DamianFierce: The FDA has changed its approach to medical device hackers, part of its new commitment to cybersecurity. Report | Follow @DamianFierce

> JenaValve lands $62.5M round for heart valve. More

> Baxter wins EU sign-off for $4B Gambro deal. News

> Medical devices help spur Israeli VC investment growth. Article

Pharma News

 @FiercePharma: Some good news for Forest Labs: Quarterly sales tick up 6% to almost $800M; Forest credits newer products. More | Follow @FiercePharma

 @CarlyHFierce: Former AstraZeneca exec Tony Zook officially in as new CEO of Vivus. News | Follow @CarlyHFierce

> China detains first U.S. citizen in pharma industry probe. Story

> GlaxoSmithKline forges ahead with hunt for Chinese vaccine partners. Article

> Biogen: Tecfidera link to MS patient's death 'unlikely.' Report

Biotech Research News

 @EmilyMFierce: Novartis MS drug prevents heart failure in animal study. Article | Follow @EmilyMFierce

> Retinas made from embryonic stem cells implanted into mice for the first time. News

> New 3-D model of diabetes target could shape drug design. Story

> Neural origins of menopausal hot flashes discovered. Item

> Revalesio drug alters Alzheimer's progression in animal model. Article

Pharma Manufacturing News

 @EricPFierce: Orphan drugs have become a key product for many companies. See why: Special report | Follow @EricPFierce

> Wockhardt FDA warning letter says QA staff tried to mislead inspectors. Report

> Drug shortages in Ireland getting worse. More

> New bill could free drug user fees from sequestration, improve oversight. Article

> Venus Remedies gets 9 Ukraine plants approved. Item

> AMRI gets issues under control at Burlington plant. Report

And Finally... A drug sold by Novartis ($NVS) to treat multiple sclerosis could potentially prevent heart failure. Story

Suggested Articles

It’s been a minute, but AstraZeneca has gotten the FDA’s all-clear to restart the U.S. study of its COVID-19 vaccine.

Combining KSQ's USP1 inhibitor with Merck and AstraZeneca's PARP inhibitor Lynparza was more effective in animal models than either drug on its own.

Solid Bio is teaming up with Ultragenyx on Duchenne muscular dystrophy in a deal worth $40 million upfront but could net it another $255 million.